Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:
“Emerging checkpoint target: LAG-3.
Combining relatlimab (anti–LAG-3) with nivolumab enhances efficacy in melanoma vs. PD-1 alone, potentially with less toxicity than CTLA-4 combos. New frontiers in solid tumors are opening.”
Title: The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies
Authors: Vinay K. Giri, David F. McDermott, Jacob Zaemes
Read The Full Article at ACS Journal.
More posts featuring Diego Díaz García.